Actively Recruiting

Age: 18Years +
All Genders
NCT07025200

DETACT sEvere asThmAtiC paTients - a Pilot Study

Led by Medical University of Vienna · Updated on 2025-06-17

10

Participants Needed

1

Research Sites

197 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

The objective of this study is to investigate the effect of dupilumab treatment on mucus plugging in severe asthma patients with severe eosinophilic asthma. Therefore, the investigators plan to apply computer tomography to investigate mucus plugging and thoroughly examine different airway samples from Type 2-high severe asthmatic patients at a cellular, molecular, microbiological and metabolomic level. This study will help to unravel underlying treatment mechanisms of dupilumab therapy in severe asthmatics.

CONDITIONS

Official Title

DETACT sEvere asThmAtiC paTients - a Pilot Study

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Be 18 years of age or older
  • Have a recorded clinical diagnosis of asthma (ICD-10 Code: J45)
  • Meet criteria for severe Type 2-high asthma treatment with Dupilumab, including FeNO > 25 ppB
  • Have at least two blood eosinophil counts of 250 cells/µl or higher, or one elevated blood eosinophil count during oral corticosteroid reduction, or sputum eosinophils ≥ 2% or BAL eosinophils ≥ 1%
  • Have completed a washout period of 2 half-lives or 1 month if previously treated with monoclonal antibodies for asthma
Not Eligible

You will not qualify if you...

  • Are pregnant as confirmed by a ß-HCG test
  • Have severe anatomical issues preventing bronchoscopy
  • Have other lung disorders such as bronchiectasis, COPD, pulmonary fibrosis, emphysema, cystic fibrosis, parasitic infections, or lung cancer
  • Have pulmonary conditions with asthma symptoms and blood eosinophilia like Churg-Strauss syndrome, allergic bronchopulmonary aspergillosis, or hypereosinophilic syndrome
  • Have mental conditions impairing understanding of the study
  • Have clinically significant comorbidities
  • Experienced an asthma exacerbation within 4 weeks before the first main visit
  • Have immune disorders or are on immunosuppressive or ongoing biological treatments for asthma within specified timeframes
  • Have a history of drug or alcohol abuse
  • Are current smokers or former smokers with less than 6 months abstinence and more than 10 pack years

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Medical University of Vienna, Clinic of Internal Medicine II, Department of Pulmonology

Vienna, State of Vienna, Austria, 1090

Actively Recruiting

Loading map...

Research Team

M

Marco Idzko, M.D.

CONTACT

S

Slagjana Stoshikj, M.D.

CONTACT

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here